Actively Recruiting
Bronchial Epithelium of Children With Post-infectious Bronchiolitis Obliterans
Led by Institut National de la Santé Et de la Recherche Médicale, France · Updated on 2025-04-25
450
Participants Needed
1
Research Sites
151 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Bronchiolitis obliterans (BO) is an irreversible chronic obstructive pulmonary pathology leading to obstruction and/or obliteration of the small airways. In children, the most common form of BO occurs following a serious lower respiratory tract infection. This is a rare complication; the incidence is unknown. The diagnosis, often late, is made on clinical, spirometric and radiological arguments. The pathophysiology would be linked to damage to the airway epithelium. PIBO is most commonly associated with adenovirus (ADV) infection (serotypes 3, 7, 11 and 21) but also other viruses such as rhinovirus (RV). The treatment of PIBO is not clearly established, it remains empirical. The research hypothesis is that the morphology of the nasal epithelium of children with ADV or RV infection is different for those progressing to PIBO. The main objective of the proposed observational study is to characterize damage to the respiratory epithelium in these children. This is a single-center prospective longitudinal study (AP-HM), in children aged 1 month to 6 years, comparing children hospitalized for lower respiratory infection by ADV or RV progressing or not to PIBO. All children included will have a nasal swab and brushing on D0. Children developing PIBO will have nasal brushing with bronchial endoscopy with bronchial biopsies and bronchoalveolar washing at the time of PIBO diagnosis and again at M6 in case of partial response to treatment. This is therefore a pilot study aimed at defining damage to the respiratory epithelium in children with PIBO following an ADV or RV infection and the role of respiratory epithelial cells in PIBO.
CONDITIONS
Official Title
Bronchial Epithelium of Children With Post-infectious Bronchiolitis Obliterans
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Children aged 1 month to 6 years hospitalized at Timone Enfant University Hospital
- Confirmed adenovirus or rhinovirus respiratory infection by nasal swab at admission
- Signed informed consent from parents before any study procedure
- Affiliation to or beneficiary of a social security scheme
- Children aged 1 month to 6 years transferred to Timone Enfant University Hospital
- Persistent clinical signs 6 weeks after viral infection: tachypnea, wheezing and/or persistent hypoxemia
- Imaging showing mosaic appearance, bronchiectasis, or atelectasis
- If lung function tests performed: obstructive ventilatory disorder not or slightly reversible after bronchodilators
- Signed informed consent from parents before any study procedure
- Affiliation to or beneficiary of a social security scheme
You will not qualify if you...
- Family refusal to participate or lack of parental authority
- Presence of underlying chronic lung disease (e.g., cystic fibrosis, ciliary dyskinesia)
- Presence of coagulation disorders
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
APHM
Marseille, France, 13000
Actively Recruiting
Research Team
J
Julie MAZENQ, PhD
CONTACT
D
Delphine Gras
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
BASIC_SCIENCE
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here